Interferons in oncology

British Journal of Clinical Practice

Volumn 51, Issue 2, 1997, Pages 111-115

  Woll, P J ^a,b,c,d   Pettengell, R ^a,b,c,d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Departments of Haematologv and Oncology   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ATAXIA; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIRY CELL LEUKEMIA; HASHIMOTO DISEASE; HUMAN; HYPOTENSION; IMMUNOMODULATION; INSOMNIA; LIVER NECROSIS; LUNG CANCER; MALAISE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SEIZURE;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERONS; KIDNEY NEOPLASMS; LEUKEMIA; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MELANOMA; NEOPLASMS; SARCOMA, KAPOSI;

EID: 0030967233     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Pmc Roy Soc bond Biol 1957; 147: 258-267.
2. Dorr RT. Interferon-alpha in malignant and viral diseases - a review. Dru^ 199?; 45: 177-211.
3. Cirelli R, Tyring SK. Major therapeutic uses of interferons. Clin Immunother 1995; 3: 27-87.
4. Golomh HM, Fefer A, Golde DW et al. Survival experience of 195 patients with hairy cell leukemia treated in a multi-institutional study with interferon-alpha-2h. Leak Lymphoma 1991; 4: 99-102.
5. Troussard X, Flandrin G. Hairy cell leukemia. An update on a cohort of 93 patients treated in a single institution: effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. Leuk Lymphoma 1994; 14(Suppl 1): 99-105.
6. Grever M. Kopecky K, Foucar MK el al. Randomized comparison ofpentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974-82.
7. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
8. Alan NC, Richards SM. Shepherd PCA. UK Medical Research Council randomised multieentre trial of interferon-anl for chronic myelogenous leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995:345: 1392-1397.
9. Hehlmann R, Heimpel J, Hasford J et al. Randomized comparison of interferon-a with husulphan and hydroxyurea in chronic myeloid leukemia. Blood 1994; 84: 4064-4077.
10. Girault S. O'Brien S, Talpaz M et al. Interferon-alfa and interleukin-2 as treatment for leukemia relapse after allogeneic transplantation. C\'tokines MolTher 1995; 1: 115-122.
11. Ludwig H. Cohen AM, Polliack A et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995: 6: 467-476.
12. Cooper MR, Dear K, Mclntyre OR et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 1993; 11: 155-160.
13. Osterhorg A, Bjorkholm M, Bjoreman M et al. Natural interfeon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81: 1428-1434.
14. Westin J, Rodjer S, Turesson I et al. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995; 89: 561-568.
15. Smalley RV, Andersen JW, Hawkins MJ et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N EnglJ Med 1992; 327: 1336-1441.
16. Solal-Celigny P, Lepage E, Brousse N el al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329: 1608-1614.
17. McLaughlin P, Cabanillas F, Hagemeister FB et al. CHOP-Bleo plus interferon for stage IV low grade lymphoma. Ann Oncol 1993; 4: 205-211.
18. Hagenbeek A, Carde P, Somers R et al. Interferon alfa 2A vs control as maintenance therapy for low grade non-Hodgkin's lymphoma: results from a prospective randomized clinical trial. Pmc Am Soc Clin Oncol 1995; 14: 386.
19. Aviles A, Duque G, Nambo MJ, Diaz Maqueo JC. Interferon alfa 2b in the maintenance therapy of low grade non-Hodgkin's lymphoma. Blood 1994;84(Suppl 1): 166.
20. Schenkein DP, Dixon P, Desforges JF et al. Phase I/II study of cyclophosphamide, carboplatin and etoposide and autologous hematopoietic stem cell transplantation with post-transplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease. J Clin Oncol 1994; 12: 2423-2431.
21. Evans LM, Itri LM, Campion M et al. Interferon-a2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J linmunother 1991; 10:39-50.
22. Thomson DB, Adena M, McLeod GR et a\. Interferon-alpha 2a does nol improve response rate or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133-138.
23. Bajetta E, Dileo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of Interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12:806-811.
24. Falkson CI. Experience with interferon-alpha-2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med Oncol 1995; 12: 35-40.
25. Lienard D. Eggermont AMM. Koops HS et al. Isolated perfusion of the limb with high-dose tumor-necrosis factor-alpha (TNF-alpha), interferongamma (IFN-gamma) and melphalan for melanoma stage III - results of a multicenter pilot study. Melanoma Res 1994; 4(Suppl 1): 21-26.
26. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Onco' 1996; 14: 7-17.
27. Fossa S, Jones M. Johnson P et al. Interferon-alpha and survival in renal cell cancer. Br J U ml 1995; 76: 286-290.
28. Kriegmair M. Oberneder R, Hofstetter A et al. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. J Uml 1995; 45: 758-762.
29. Atzpodien J, Hanninen EL, Kirchner H et al. Multi-institutional home therapy trial of recombinant human interleukin-2 and Interferon alpha-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995; 13: 497-501.
30. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180-199.
31. Öberg KE. The role of interferons in human neuroendocrine tumours and aspects of mechanisms of action. In: Crowther D, Ed. Interferons: mechanisms of action and role in cancer therapy. Berlin: Springer Verlag, 1991.43-52.
32. Janson ET, Ronnblom L, Ahlstrom H et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozotocin and doxorubicin in patients with malignant carcinoid tumours: a randomized trial. Ann Oncol 1992; 3: 635-638.
33. Wadler S, Schwanz EL, Goldman M et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ,/ Clin Oncol 1989; 7: 1769-1775.
34. Raderer M, Scheithauer W. Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-a: an overview of clinical trials. Eur J Cancer 1995; 31A: 1002-1008.
35. Mattson K, Niiranen A, Pyrhönen S et al. Interferon maintenance therapy for small cell lung cancer: long term survival. Lung Cancer 1994; ll(Suppl 1): 99 (abstract 374).
36. Mattson K, Niiranen A, Pyrhönen S et al. Natural Interferon alpha as maintenance therapy for small cell lung cancer. Eur J Cancer 1992; 28A: 1387-1391.
37. Kelly K, Crowley JJ, Bunn PA et al. Role of recombinant Interferon alfa2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 2924-2930.
38. Jett JR, Maksymiuk AW, Su JQ et al. Phase III trial of recombinant Interferon gamma in complete responders with small cell lung cancer. J Clin Oncol 1994; 12: 2321-2326.
39. McDonald S, Chang AY, Rubin P et al. Combined Betaseron-R (recombinant human inteferon-beta) and radiation for inoperable non-small-cell lung-cancer. Int J Radiât Oncol Biol Phys 1993; 27: 613-619.
40. Ardizzoni A, Salvati F, Rosso R et al. Combination of chemotherapy and recombinant alpha-interferon in advanced non small cell lung-cancer multicentric randomized Fonicap trial report. Cancer 1993; 72: 2929-2935.
41. Ardizzoni A, Addamo GF, Baldini E et al. Mitomycin-ifosfamide-cisplatin (MIP) vs MlP-interferon vs cisplatin-carboplatin in metastatic nonsmall-cell lung-cancer - a Fonicap randomized phase II study. Br J Cancer 1995; 71: 115-119.
42. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.